Trial Outcomes & Findings for Head-up Tilt Test in Patients With Reflex Syncope and Asystolic Response Who Received a Dual-chamber Pacemaker With the Closed Loop Stimulation (CLS) and Participated in the BIOSync Trial (NCT NCT06038708)

NCT ID: NCT06038708

Last Updated: 2025-02-03

Results Overview

Instantaneous measurement of heart rate value at specific time-points/stages during HUTT examination. Changes in Heart rate were investigated across four stages of the HUTT: baseline (Stage 1), pre-syncopal phase (Stage 2), maximum heart rate/pacing rate (Stage 3), and syncope or lowest Systolic Blood Pressure (Stage 4).

Recruitment status

COMPLETED

Target enrollment

20 participants

Primary outcome timeframe

From the start to the end of the HUTT examination, assessed up to 45 minutes

Results posted on

2025-02-03

Participant Flow

Participant milestones

Participant milestones
Measure
DDD-CLS Patients
Patients with reflex syncope and positive cardioinhibitory response to Head-Up Tilt Test (HUTT) with a dual-chamber pacing system equipped with the CLS algorithm.
Overall Study
STARTED
20
Overall Study
COMPLETED
20
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
DDD-CLS Patients
n=20 Participants
Patients with reflex syncope and positive cardioinhibitory response to Head-Up Tilt Test (HUTT) with a dual-chamber pacing system equipped with the CLS algorithm.
Age, Continuous
68.3 years
STANDARD_DEVIATION 11.9 • n=20 Participants
Sex: Female, Male
Female
4 Participants
n=20 Participants
Sex: Female, Male
Male
16 Participants
n=20 Participants
Region of Enrollment
Italy
20 Participants
n=20 Participants

PRIMARY outcome

Timeframe: From the start to the end of the HUTT examination, assessed up to 45 minutes

Instantaneous measurement of heart rate value at specific time-points/stages during HUTT examination. Changes in Heart rate were investigated across four stages of the HUTT: baseline (Stage 1), pre-syncopal phase (Stage 2), maximum heart rate/pacing rate (Stage 3), and syncope or lowest Systolic Blood Pressure (Stage 4).

Outcome measures

Outcome measures
Measure
DDD-CLS Patients
n=14 Participants
Patients with reflex syncope and positive cardioinhibitory response to Head-Up Tilt Test (HUTT) with a dual-chamber pacing system equipped with the CLS algorithm.
Heart Rate [Bpm] at Specific Time-points During Head-up Tilt Test (HUTT) Examination
Heart rate at baseline (Stage 1)
70 beats per minute
Standard Deviation 7
Heart Rate [Bpm] at Specific Time-points During Head-up Tilt Test (HUTT) Examination
Heart rate at pre-syncopal phase (Stage 2)
88 beats per minute
Standard Deviation 12
Heart Rate [Bpm] at Specific Time-points During Head-up Tilt Test (HUTT) Examination
Heart rate at maximum HR/pacing rate (Stage 3)
105 beats per minute
Standard Deviation 14
Heart Rate [Bpm] at Specific Time-points During Head-up Tilt Test (HUTT) Examination
Heart rate at syncope or lowest Systolic Blood Pressure (Stage 4)
95 beats per minute
Standard Deviation 13

PRIMARY outcome

Timeframe: From the start to the end of the HUTT examination, assessed up to 45 minutes

Instantaneous measurement of blood pressure at specific time-points during HUTT examination. Changes in Systolic blood pressure were investigated across four stages of the HUTT: baseline (Stage 1), pre-syncopal phase (Stage 2), maximum heart rate/pacing rate (Stage 3), and syncope or lowest Systolic Blood Pressure (Stage 4).

Outcome measures

Outcome measures
Measure
DDD-CLS Patients
n=14 Participants
Patients with reflex syncope and positive cardioinhibitory response to Head-Up Tilt Test (HUTT) with a dual-chamber pacing system equipped with the CLS algorithm.
Systolic Blood Pressure at Specific Time-points During Head-up Tilt Test (HUTT) Examination
Systolic blood pressure at baseline (Stage 1)
143 mmHg
Standard Deviation 20
Systolic Blood Pressure at Specific Time-points During Head-up Tilt Test (HUTT) Examination
Systolic blood pressure at pre-syncopal phase (Stage 2)
108 mmHg
Standard Deviation 19
Systolic Blood Pressure at Specific Time-points During Head-up Tilt Test (HUTT) Examination
Systolic blood pressure at maximum heart rate/pacing rate (Stage 3)
99 mmHg
Standard Deviation 21
Systolic Blood Pressure at Specific Time-points During Head-up Tilt Test (HUTT) Examination
Systolic blood pressure at syncope or lowest Systolic Blood Pressure (Stage 4)
63 mmHg
Standard Deviation 17

PRIMARY outcome

Timeframe: From the start to the end of the HUTT examination, assessed up to 45 minutes

Instantaneous measurement of stroke volume at specific time-points during HUTT examination

Outcome measures

Outcome measures
Measure
DDD-CLS Patients
n=14 Participants
Patients with reflex syncope and positive cardioinhibitory response to Head-Up Tilt Test (HUTT) with a dual-chamber pacing system equipped with the CLS algorithm.
Stroke Volume [ml] at Specific Time-points During Head-up Tilt Test (HUTT)
Stroke volume at time of maximum spontaneous heart rate
54.6 ml
Standard Deviation 10.4
Stroke Volume [ml] at Specific Time-points During Head-up Tilt Test (HUTT)
Stroke volume at time of maximum CLS pacing rate
47 ml
Standard Deviation 8.4
Stroke Volume [ml] at Specific Time-points During Head-up Tilt Test (HUTT)
Stroke volume at time of recovery of basic pacing rate or spontaneous rhythm after pacing
77.9 ml
Standard Deviation 34.5

PRIMARY outcome

Timeframe: From the start to the end of the HUTT examination, assessed up to 45 minutes

Instantaneous measurement of peripheral resistance at specific time-points during HUTT examination

Outcome measures

Outcome measures
Measure
DDD-CLS Patients
n=14 Participants
Patients with reflex syncope and positive cardioinhibitory response to Head-Up Tilt Test (HUTT) with a dual-chamber pacing system equipped with the CLS algorithm.
Peripheral Resistance [Dyn·s/cm5] at Specific Time-points During Head-up Tilt Test (HUTT)
Peripheral Resistance at time of maximum spontaneous heart rate
1262.5 dyn*s/cm^5
Standard Deviation 377
Peripheral Resistance [Dyn·s/cm5] at Specific Time-points During Head-up Tilt Test (HUTT)
Peripheral Resistance at time of maximum CLS pacing rate
1226.2 dyn*s/cm^5
Standard Deviation 350.4
Peripheral Resistance [Dyn·s/cm5] at Specific Time-points During Head-up Tilt Test (HUTT)
Peripheral Resistance at time of recovery of basic pacing rate or spontaneous rhythm after pacing
1183.8 dyn*s/cm^5
Standard Deviation 347.3

PRIMARY outcome

Timeframe: From the start to the end of the HUTT examination, assessed up to 45 minutes

Recording of a specific time-point during HUTT examination. This time was collected as hours:minutes:seconds (e.g. 00:35:34).

Outcome measures

Outcome measures
Measure
DDD-CLS Patients
n=14 Participants
Patients with reflex syncope and positive cardioinhibitory response to Head-Up Tilt Test (HUTT) with a dual-chamber pacing system equipped with the CLS algorithm.
Time of Maximum Spontaneous Heart Rate
22.7 minutes
Interval 21.6 to 24.6

PRIMARY outcome

Timeframe: From the start to the end of the HUTT examination, assessed up to 45 minutes

Recording of a specific time-point during HUTT examination. This time was collected as hours:minutes:seconds (e.g. 00:35:34).

Outcome measures

Outcome measures
Measure
DDD-CLS Patients
n=14 Participants
Patients with reflex syncope and positive cardioinhibitory response to Head-Up Tilt Test (HUTT) with a dual-chamber pacing system equipped with the CLS algorithm.
Time of Pacing Onset
22.9 minutes
Interval 22.0 to 24.4

PRIMARY outcome

Timeframe: From the start to the end of the HUTT examination, assessed up to 45 minutes

Recording of a specific time-point during HUTT examination. This time was collected as hours:minutes:seconds (e.g. 00:35:34).

Outcome measures

Outcome measures
Measure
DDD-CLS Patients
n=14 Participants
Patients with reflex syncope and positive cardioinhibitory response to Head-Up Tilt Test (HUTT) with a dual-chamber pacing system equipped with the CLS algorithm.
Time of Recovery of Spontaneous Rhythm After Pacing
29.2 minutes
Interval 26.4 to 32.5

PRIMARY outcome

Timeframe: From the start to the end of the HUTT examination, assessed up to 45 minutes

Recording of a specific time-point during HUTT examination. This time was collected as hours:minutes:seconds (e.g. 00:35:34).

Outcome measures

Outcome measures
Measure
DDD-CLS Patients
n=14 Participants
Patients with reflex syncope and positive cardioinhibitory response to Head-Up Tilt Test (HUTT) with a dual-chamber pacing system equipped with the CLS algorithm.
Time of Syncope
24.0 minutes
Interval 22.9 to 25.2

PRIMARY outcome

Timeframe: From the start to the end of the HUTT examination, assessed up to 45 minutes

Recording of a specific time-point during HUTT examination. This time was collected as hours:minutes:seconds (e.g. 00:35:34).

Outcome measures

Outcome measures
Measure
DDD-CLS Patients
n=14 Participants
Patients with reflex syncope and positive cardioinhibitory response to Head-Up Tilt Test (HUTT) with a dual-chamber pacing system equipped with the CLS algorithm.
Time of Tilt-down
25.3 minutes
Interval 23.4 to 37.6

PRIMARY outcome

Timeframe: From the start to the end of the HUTT examination, assessed up to 45 minutes

Interval from maximum pacing rate to basic rate or spontaneous rhythm

Outcome measures

Outcome measures
Measure
DDD-CLS Patients
n=14 Participants
Patients with reflex syncope and positive cardioinhibitory response to Head-Up Tilt Test (HUTT) with a dual-chamber pacing system equipped with the CLS algorithm.
Duration of the Recovery Phase [Minutes]
5.0 minutes
Interval 3.3 to 8.3

PRIMARY outcome

Timeframe: From the start to the end of the HUTT examination, assessed up to 45 minutes

Calculation of the rate of change of heart rate from the time of maximum pacing rate to the time of basic rate or spontaneous rhythm recovery

Outcome measures

Outcome measures
Measure
DDD-CLS Patients
n=14 Participants
Patients with reflex syncope and positive cardioinhibitory response to Head-Up Tilt Test (HUTT) with a dual-chamber pacing system equipped with the CLS algorithm.
Slope in Heart Rate [Bpm/Minute] During the Recovery Phase
-6.0 bpm/minute
Standard Deviation 3.0

PRIMARY outcome

Timeframe: From the start to the end of the HUTT examination, assessed up to 45 minutes

Calculation of the rate of change of systolic blood pressure from the time of maximum pacing rate to the time of basic rate or spontaneous rhythm recovery

Outcome measures

Outcome measures
Measure
DDD-CLS Patients
n=14 Participants
Patients with reflex syncope and positive cardioinhibitory response to Head-Up Tilt Test (HUTT) with a dual-chamber pacing system equipped with the CLS algorithm.
Slope in Systolic Blood Pressure (mmHg Per Minute) During the Recovery Phase
6.2 mmHg per minute
Standard Deviation 11.5

POST_HOC outcome

Timeframe: From the start to the end of the HUTT examination, assessed up to 45 minutes

Time interval from CLS pacing onset to syncope or lowest blood pressure \[minutes\]

Outcome measures

Outcome measures
Measure
DDD-CLS Patients
n=14 Participants
Patients with reflex syncope and positive cardioinhibitory response to Head-Up Tilt Test (HUTT) with a dual-chamber pacing system equipped with the CLS algorithm.
Onset of CLS Pacing
1.7 minutes
Interval 1.5 to 3.4

POST_HOC outcome

Timeframe: From the start to the end of the HUTT examination, assessed up to 45 minutes

Total duration of CLS pacing (interval from pacing onset to recovery of basic rate or spontaneous rhythm) \[minutes\]

Outcome measures

Outcome measures
Measure
DDD-CLS Patients
n=14 Participants
Patients with reflex syncope and positive cardioinhibitory response to Head-Up Tilt Test (HUTT) with a dual-chamber pacing system equipped with the CLS algorithm.
Duration of CLS Pacing
5.0 minutes
Interval 3.3 to 8.3

Adverse Events

DDD-CLS Patients

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Paola Napoli, Clinical Project Manager

BIOTRONIK Italy

Phone: 3357369277

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place